The DOI matches its Crossref record; 154 of the 154 references it cites were found in a registry or an index.
Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway
Open accessAbstract
Transforming growth factor-beta (TGF-β) signaling regulates a wide range of biological processes. TGF-β plays an important role in tumorigenesis and contributes to the hallmarks of cancer, including tumor proliferation, invasion and metastasis, inflammation, angiogenesis, and escape of immune surveillance. There are several pharmacological approaches to block TGF-β signaling, such as monoclonal antibodies, vaccines, antisense oligonucleotides, and small molecule inhibitors. Galunisertib (LY2157299 monohydrate) is an oral small molecule inhibitor of the TGF-β receptor I kinase that specifically downregulates the phosphorylation of SMAD2, abrogating activation of the canonical pathway. Furthermore, galunisertib has antitumor activity in tumor-bearing animal models such as breast, colon, lung cancers, and hepatocellular carcinoma. Continuous long-term exposure to galunisertib caused cardiac toxicities in animals requiring adoption of a pharmacokinetic/pharmacodynamic-based dosing strategy to allow further development. The use of such a pharmacokinetic/pharmacodynamic model defined a therapeutic window with an appropriate safety profile that enabled the clinical investigation of galunisertib. These efforts resulted in an intermittent dosing regimen (14 days on/14 days off, on a 28-day cycle) of galunisertib for all ongoing trials. Galunisertib is being investigated either as monotherapy or in combination with standard antitumor regimens (including nivolumab) in patients with cancer with high unmet medical needs such as glioblastoma, pancreatic cancer, and hepatocellular carcinoma. The present review summarizes the past and current experiences with different pharmacological treatments that enabled galunisertib to be investigated in patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Molecular mechanisms of epithelial–mesenchymal transition
Lamouille, S., Xu, J., & Derynck, R. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3758 · Cited by 8,091
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
TGFβ Signaling in Growth Control, Cancer, and Heritable Disorders
Massagué, J., Blain, S. W., & Lo, R. S. (2000) · Cell · doi:10.1016/s0092-8674(00)00121-5 · Cited by 2,385
DPC4 , A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1
Hahn, S. A., Schutte, M., Shamsul Hoque, A. T. M., Moskaluk, C. A., da Costa, L. T., Rozenblum, E., Weinstein, C. L., Fischer, A., Yeo, C. J., Hruban, R. H., et al. (1996) · Science · doi:10.1126/science.271.5247.350 · Cited by 2,337
TGF-β signaling and the fibrotic response
Leask, A., & Abraham, D. J. (2004) · The FASEB Journal · doi:10.1096/fj.03-1273rev · Cited by 2,319
TGF-β Signaling in Tumor Suppression and Cancer Progression
Derynck, R., Akhurst, R. J., & Balmain, A. (2001) · Nature Genetics · doi:10.1038/ng1001-117 · Cited by 2,275
Aneurysm Syndromes Caused by Mutations in the TGF-β Receptor
Loeys, B. L., Schwarze, U., Holm, T., Callewaert, B. L., Thomas, G. H., Pannu, H., De Backer, J. F., Oswald, G. L., Symoens, S., Manouvrier, S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055695 · Cited by 1,663
Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer
Siegel, P. M., & Massagué, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1208 · Cited by 1,604
Kehrl, J. H., Wakefield, L. M., Roberts, A. B., Jakowlew, S., Alvarez-Mon, M., Derynck, R., Sporn, M. B., & Fauci, A. S. (1986) · The Journal of experimental medicine · doi:10.1084/jem.163.5.1037 · Cited by 1,582
TGFβ signals through a heteromeric protein kinase receptor complex
Wrana, J. L., Attisano, L., Cárcamo, J., Zentella, A., Doody, J., Laiho, M., Wang, X.-F., & Massague, J. (1992) · Cell · doi:10.1016/0092-8674(92)90395-s · Cited by 1,526
Hallmarks of Cancer: The Next Generation
Roizen, M. F. (2012) · Yearbook of Anesthesiology and Pain Management · doi:10.1016/j.yane.2012.02.046 · Cited by 1,501
Targeting the TGFβ signalling pathway in disease
Akhurst, R. J., & Hata, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3810 · Cited by 1,466
Dependency of Colorectal Cancer on a TGF-β-Driven Program in Stromal Cells for Metastasis Initiation
Calon, A., Espinet, E., Palomo-Ponce, S., Tauriello, D. V. F., Iglesias, M., Céspedes, M. V., Sevillano, M., Nadal, C., Jung, P., Zhang, X. H.-F., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.013 · Cited by 1,060
The polarization of immune cells in the tumour environment by TGFβ
Flavell, R. A., Sanjabi, S., Wrzesinski, S. H., & Licona-Limón, P. (2010) · Nature Reviews Immunology · doi:10.1038/nri2808 · Cited by 940
Roberts, A. B., Anzano, M. A., Lamb, L. C., Smith, J. M., & Sporn, M. B. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.9.5339 · Cited by 919
The roles of TGFβ in the tumour microenvironment
Pickup, M., Novitskiy, S., & Moses, H. L. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3603 · Cited by 917
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
Sun, C., Wang, L., Huang, S., Heynen, G. J. J. E., Prahallad, A., Robert, C., Haanen, J., Blank, C., Wesseling, J., Willems, S. M., et al. (2014) · Nature · doi:10.1038/nature13121 · Cited by 888
Specificity, diversity, and regulation in TGF-beta superfamily signaling.
Piek, E., HELDIN, C., & ten Dijke, P. (1999) · PubMed · Cited by 783
TGF- β signaling in cancer – a double-edged sword
Akhurst, R. J., & Derynck, R. (2001) · Trends in Cell Biology · doi:10.1016/s0962-8924(01)02130-4 · Cited by 756
The transforming growth factor-β system, a complex pattern of cross-reactive ligands and receptors
Cheifetz, S., Weatherbee, J. A., Tsang, M. L.-S., Anderson, J. K., Mole, J. E., Lucas, R., & Massagué, J. (1987) · Cell · doi:10.1016/0092-8674(87)90192-9 · Cited by 706
Wieser, R., Wrana, J. L., & Massagué, J. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07214.x · Cited by 699
Role of transforming growth factor-β superfamily signaling pathways in human disease
Gordon, K. J., & Blobe, G. C. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.01.006 · Cited by 641
Loeffler, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26532 · Cited by 633
TGF-β signaling in vascular biology and dysfunction
Goumans, M.-J., Liu, Z., & ten Dijke, P. (2009) · Cell Research · doi:10.1038/cr.2008.326 · Cited by 601
TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer
Bhola, N. E., Balko, J. M., Dugger, T. C., Kuba, M. G., Sánchez, V., Sanders, M., Stanford, J., Cook, R. S., & Arteaga, C. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65416 · Cited by 590
Anido, J., Sáez-Borderías, A., Gonzàlez-Juncà, A., Rodón, L., Folch, G., Carmona, M. A., Prieto-Sánchez, R. M., Barba, I., Martínez-Sáez, E., Prudkin, L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.023 · Cited by 572
Self-citationDevelopment of TGF-β signalling inhibitors for cancer therapy
Yingling, J. M., Blanchard, K. L., & Sawyer, J. S. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1580 · Cited by 549
Self-citationAlterations in components of the TGF-β superfamily signaling pathways in human cancer
LEVY, L., & HILL, C. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.09.009 · Cited by 539
Leof, E. B., Proper, J. A., Goustin, A. S., Shipley, G. D., DiCorleto, P. E., & Moses, H. L. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.8.2453 · Cited by 529
Peñuelas, S., Anido, J., Prieto-Sánchez, R. M., Folch, G., Barba, I., Cuartas, I., García-Dorado, D., Poca, M. A., Sahuquillo, J., Baselga, J., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.02.011 · Cited by 526
Simeoni, M., Magni, P., Cammia, C., De Nicolao, G., Croci, V., Pesenti, E., Germani, M., Poggesi, I., & Rocchetti, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2524 · Cited by 506
Morris, J. C., Tan, A. R., Olencki, T. E., Shapiro, G. I., Dezube, B. J., Reiss, M., Hsu, F. J., Berzofsky, J. A., & Lawrence, D. P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090353 · Cited by 487
Loss-of-function mutations in TGFB2 cause a syndromic presentation of thoracic aortic aneurysm
Lindsay, M. E., Schepers, D., Bolar, N. A., Doyle, J. J., Gallo, E., Fert-Bober, J., Kempers, M. J. E., Fishman, E. K., Chen, Y., Myers, L., et al. (2012) · Nature Genetics · doi:10.1038/ng.2349 · Cited by 482
Noncanonical TGFβ Signaling Contributes to Aortic Aneurysm Progression in Marfan Syndrome Mice
Holm, T. M., Habashi, J. P., Doyle, J. J., Bedja, D., Chen, Y., van Erp, C., Lindsay, M. E., Kim, D., Schoenhoff, F., Cohn, R. D., et al. (2011) · Science · doi:10.1126/science.1192149 · Cited by 476
Bruna, A., Darken, R. S., Rojo, F., Ocaña, A., Peñuelas, S., Arias, A., Paris, R., Tortosa, A., Mora, J., Baselga, J., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.023 · Cited by 472
Roberts, A. B., Lamb, L. C., Newton, D. L., Sporn, M. B., De Larco, J. E., & Todaro, G. J. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.6.3494 · Cited by 448
Bogdahn, U., Hau, P., Stockhammer, G., Venkataramana, N. K., Mahapatra, A. K., Suri, A., Balasubramaniam, A., Nair, S., Oliushine, V., Parfenov, V., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq142 · Cited by 433
MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling
Huang, S., Hölzel, M., Knijnenburg, T., Schlicker, A., Roepman, P., McDermott, U., Garnett, M., Grernrum, W., Sun, C., Prahallad, A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.10.035 · Cited by 430
Kano, M. R., Bae, Y., Iwata, C., Morishita, Y., Yashiro, M., Oka, M., Fujii, T., Komuro, A., Kiyono, K., Kaminishi, M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611660104 · Cited by 410
Lonardo, E., Hermann, P. C., Mueller, M.-T., Huber, S., Balic, A., Miranda-Lorenzo, I., Zagorac, S., Alcala, S., Rodriguez-Arabaolaza, I., Ramirez, J. C., et al. (2011) · Cell Stem Cell · doi:10.1016/j.stem.2011.10.001 · Cited by 405
Yang, Y.-A., Dukhanina, O., Tang, B., Mamura, M., Letterio, J. J., MacGregor, J., Patel, S. C., Khozin, S., Liu, Z.-Y., Green, J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200215333 · Cited by 404
Yang, Y.-A., Dukhanina, O. I., Tang, B., Mamura, M., Letterio, J. J., MacGregor, J., Patel, S. C., Khozin, S., Liu, Z.-Y., Green, J. D., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15333 · Cited by 404
Grady, W. M., Myeroff, L. L., Swinler, S. E., Rajput, A., Thiagalingam, S., Lutterbaugh, J., Neumann, A., Brattain, M. G., Chang, J., Kim, S., et al. (1999) · PubMed · Cited by 391
Arteaga, C. L., Hurd, S. D., Winnier, A. R., Johnson, M. D., Fendly, B. M., & Forbes, J. T. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116871 · Cited by 359
Roepman, P., Schlicker, A., Tabernero, J., Majewski, I., Tian, S., Moreno, V., Snel, M. H., Chresta, C. M., Rosenberg, R., Nitsche, U., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28387 · Cited by 346
Biswas, S., Guix, M., Rinehart, C., Dugger, T. C., Chytil, A., Moses, H. L., Freeman, M. L., & Arteaga, C. L. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30740 · Cited by 346
Melisi, D., Ishiyama, S., Sclabas, G. M., Fleming, J. B., Xia, Q., Tortora, G., Abbruzzese, J. L., & Chiao, P. J. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0337 · Cited by 323
Induction of Heart Valve Lesions by Small-Molecule ALK5 Inhibitors
Anderton, M. J., Mellor, H. R., Bell, A., Sadler, C., Pass, M., Powell, S., Steele, S. J., Roberts, R. R. A., & Heier, A. (2011) · Toxicologic Pathology · doi:10.1177/0192623311416259 · Cited by 284
Synergistic interaction of two classes of transforming growth factors from murine sarcoma cells.
Anzano, M. A., Roberts, A. B., Meyers, C. A., Komoriya, A., Lamb, L. C., Smith, J. M., & Sporn, M. B. (1982) · PubMed · Cited by 265
Transforming Growth Factor-β as a Therapeutic Target in Hepatocellular Carcinoma
Giannelli, G., Villa, E., & Lahn, M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0243 · Cited by 263
Self-citationTrachtman, H., Fervenza, F. C., Gipson, D. S., Heering, P., Jayne, D. R. W., Peters, H., Rota, S., Remuzzi, G., Rump, L. C., Sellin, L. K., et al. (2011) · Kidney International · doi:10.1038/ki.2011.33 · Cited by 263
Targeting the transforming growth factor-β signaling pathway in human cancer
Nagaraj, N. S., & Datta, P. K. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903382609 · Cited by 262
Shariat, S. F., Andrews, B., Kattan, M. W., Kim, J., Wheeler, T. M., & Slawin, K. M. (2001) · Urology · doi:10.1016/s0090-4295(01)01405-4 · Cited by 261
Fransvea, E., Angelotti, U., Antonaci, S., & Giannelli, G. (2008) · Hepatology · doi:10.1002/hep.22201 · Cited by 253
Giannelli, G., Bergamini, C., Fransvea, E., Sgarra, C., & Antonaci, S. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.09.055 · Cited by 252
Zhang, M., Kleber, S., Röhrich, M., Timke, C., Han, N., Tuettenberg, J., Martin-Villalba, A., Debus, J., Peschke, P., Wirkner, U., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1212 · Cited by 249
Self-citationPlasma transforming growth factor β1 as a predictor of radiation pneumonitis
Anscher, M. S., Kong, F.-M., Andrews, K., Clough, R., Marks, L. B., Bentel, G., & Jirtle, R. L. (1998) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(98)00154-0 · Cited by 249
Hardee, M. E., Marciscano, A. E., Medina-Ramirez, C. M., Zagzag, D., Narayana, A., Lonning, S. M., & Barcellos-Hoff, M. H. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0546 · Cited by 246
Arteaga, C. L., Tandon, A. K., Hoff, D. D. V., & Osborne, C. K. (1988) · PubMed · Cited by 245
Sawyer, J. S., Anderson, B. D., Beight, D. W., Campbell, R. M., Jones, M. L., Herron, D. K., Lampe, J. W., McCowan, J. R., McMillen, W. T., Mort, N., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0205705 · Cited by 236
Self-citationRodon, J., Carducci, M. A., Sepulveda-Sánchez, J. M., Azaro, A., Calvo, E., Seoane, J., Braña, I., Sicart, E., Gueorguieva, I., Cleverly, A. L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1380 · Cited by 235
Self-citationThe prince of medicine: Galen in the Roman Empire
(2014) · Choice Reviews Online · doi:10.5860/choice.51-3284 · Cited by 226
Korpal, M., Yan, J., Lu, X., Xu, S., Lerit, D. A., & Kang, Y. (2009) · Nature Medicine · doi:10.1038/nm.1943 · Cited by 217
Shariat, S. F., Shalev, M., Menesses-Diaz, A., Kim, I. Y., Kattan, M. W., Wheeler, T. M., & Slawin, K. M. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.11.2856 · Cited by 214
Bueno, L., de Alwis, D. P., Pitou, C., Yingling, J., Lahn, M., Glatt, S., & Trocóniz, I. F. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2007.10.008 · Cited by 201
Self-citationBasics of TGF-ß and Pancreatic Cancer
Truty, M. J., & Urrutia, R. (2007) · Pancreatology · doi:10.1159/000108959 · Cited by 185
Bandyopadhyay, A., Agyin, J. K., Wang, L., Tang, Y., Lei, X., Story, B. M., Cornell, J. E., Pollock, B. H., Mundy, G. R., & Sun, L.-Z. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3565 · Cited by 185
Inhibition of the TGF-β receptor I kinase promotes hematopoiesis in MDS
Zhou, L., Nguyen, A. N., Sohal, D., Ying Ma, J., Pahanish, P., Gundabolu, K., Hayman, J., Chubak, A., Mo, Y., Bhagat, T. D., et al. (2008) · Blood · doi:10.1182/blood-2008-02-139824 · Cited by 184
Ehata, S., Hanyu, A., Fujime, M., Katsuno, Y., Fukunaga, E., Goto, K., Ishikawa, Y., Nomura, K., Yokoo, H., Shimizu, T., et al. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2006.00357.x · Cited by 180
Mazzocca, A., Fransvea, E., Dituri, F., Lupo, L., Antonaci, S., & Giannelli, G. (2010) · Hepatology · doi:10.1002/hep.23285 · Cited by 176
Tumor markers in prostate cancer I: Blood-based markers
Shariat, S. F., Semjonow, A., Lilja, H., Savage, C., Vickers, A. J., & Bjartell, A. (2011) · Acta Oncologica · doi:10.3109/0284186x.2010.542174 · Cited by 174
Ganapathy, V., Ge, R., Grazioli, A., Xie, W., Banach-Petrosky, W., Kang, Y., Lonning, S., McPherson, J., Yingling, J. M., Biswas, S., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-122 · Cited by 168
Scott Sawyer, J., Beight, D. W., Britt, K. S., Anderson, B. D., Campbell, R. M., Goodson, T., Herron, D. K., Li, H.-Y., McMillen, W. T., Mort, N., et al. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.04.007 · Cited by 166
Wang, S. E., Xiang, B., Guix, M., Olivares, M. G., Parker, J., Chung, C. H., Pandiella, A., & Arteaga, C. L. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00787-08 · Cited by 165
Shariat, S. F., Kattan, M. W., Traxel, E., Andrews, B., Zhu, K., Wheeler, T. M., & Slawin, K. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0768-03 · Cited by 165
Jin, C. H., Krishnaiah, M., Sreenu, D., Subrahmanyam, V. B., Rao, K. S., Lee, H. J., Park, S.-J., Park, H.-J., Lee, K., Sheen, Y. Y., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500115w · Cited by 162
Signal Processing in the TGF-β Superfamily Ligand-Receptor Network
Vilar, J. M. G., Jansen, R., & Sander, C. (2005) · PLoS Computational Biology · doi:10.1371/journal.pcbi.0020003 · Cited by 160
Flechsig, P., Dadrich, M., Bickelhaupt, S., Jenne, J., Hauser, K., Timke, C., Peschke, P., Hahn, E. W., Gröne, H., Yingling, J. M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2855 · Cited by 160
Self-citationTransforming growth factor-β in breast cancer: A working hypothesis
Reiß, M., & Barcellos‐Hoff, M. H. (1997) · Breast Cancer Research and Treatment · doi:10.1023/a:1005865812918 · Cited by 154
Zhou, L., McMahon, C. M., Bhagat, T. D., Alencar, C., Yu, Y., Fazzari, M. J., Sohal, D. P. S., Heuck, C. J., Gundabolu, K., Ng, C., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2933 · Cited by 140
Self-citationFransvea, E., Mazzocca, A., Antonaci, S., & Giannelli, G. (2008) · Hepatology · doi:10.1002/hep.22731 · Cited by 140
Muraoka-Cook, R. S., Shin, I., Yi, J. Y., Easterly, E., Barcellos‐Hoff, M. H., Yingling, J. M., Zent, R., & Arteaga, C. L. (2005) · Oncogene · doi:10.1038/sj.onc.1208964 · Cited by 139
Shear Stress as an Inhibitor of Vascular Smooth Muscle Cell Proliferation
Ueba, H., Kawakami, M., & Yaginuma, T. (1997) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.17.8.1512 · Cited by 137
Transforming growth factor betas and their signaling receptors in human hepatocellular carcinoma
Abou-Shady, M. A., Baer, H. U., Friess, H., Berberat, P. O., Zimmermann, A., Graber, H. U., Gold, L. I., Korc, M., & Büchler, M. W. (1999) · The American Journal of Surgery · doi:10.1016/s0002-9610(99)00012-4 · Cited by 133
Grassian, A. R., Lin, F., Barrett, R., Liu, Y., Jiang, W., Korpal, M., Astley, H. M., Gitterman, D. P., Henley, T., Howes, R., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.417832 · Cited by 129
Transforming growth factor-β signaling: emerging stem cell target in metastatic breast cancer?
Tan, A. R., Alexe, G., & Reiß, M. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0184-1 · Cited by 128
Mazzocca, A., Fransvea, E., Lavezzari, G., Antonaci, S., & Giannelli, G. (2009) · Hepatology · doi:10.1002/hep.23118 · Cited by 127
Zhong, Z., Carroll, K. D., Policarpio, D., Osborn, C., Gregory, M., Bassi, R., Jimenez, X., Prewett, M., Liebisch, G., Persaud, K., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1634 · Cited by 123
TGF‐β signalling is mediated by two autonomously functioning TβRI:TβRII pairs
Huang, T., David, L., Mendoza, V., Yang, Y., Villarreal, M. M., De, K., Sun, L., Fang, X., López‐Casillas, F., Wrana, J. L., et al. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.54 · Cited by 123
DeLong, P. A., Carroll, R. G., Henry, A. C., Tanaka, T. N., Ahmad, S., Leibowitz, M. S., Sterman, D. H., June, C. H., Albelda, S. Μ., & Vonderheide, R. H. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.3.1644 · Cited by 120
EW-7197, a Novel ALK-5 Kinase Inhibitor, Potently Inhibits Breast to Lung Metastasis
Son, J. Y., Park, S.-Y., Kim, S., Lee, S. J., Park, S.-A., Kim, M.-J., Kim, S. W., Kim, D., Nam, J., & Sheen, Y. Y. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0903 · Cited by 116
Rodon, J. A., Carducci, M. A., Sepúlveda-Sánchez, J. M., Azaro, A., Calvo, E., Seoane, J., Braña, I., Sicart, E., Gueorguieva, I., Cleverly, A., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0192-4 · Cited by 110
Self-citationKovacs, R. J., Maldonado, G., Azaro, A., Fernández, M. S., Romero, F. L., Sepulveda-Sánchez, J. M., Corretti, M., Carducci, M., Dolan, M., Gueorguieva, I., et al. (2015) · Cardiovascular Toxicology · doi:10.1007/s12012-014-9297-4 · Cited by 108
Self-citationTGFβ restores hematopoietic homeostasis after myelosuppressive chemotherapy
Brenet, F. A., Kermani, P., Spektor, R., Rafii, S., & Scandura, J. M. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20121610 · Cited by 106
Peng, S.-B., Yan, L., Xia, X., Watkins, S. A., Brooks, H. B., Beight, D. W., Herron, D. K., Jones, M. L., Lampe, J. W., McMillen, W. T., et al. (2005) · Biochemistry · doi:10.1021/bi048851x · Cited by 100
Self-citationLiu, Z., Kobayashi, K., van Dinther, M., van Heiningen, S. H., Valdimarsdóttir, G., van Laar, T., Scharpfenecker, M., Löwik, C. W. G. M., Goumans, M., ten Dijke, P., et al. (2009) · Journal of Cell Science · doi:10.1242/jcs.048942 · Cited by 95
Zhang, M., Herion, T., Timke, C., Han, N., Hauser, K., Weber, K. J., Peschke, P., Wirkner, U., Lahn, M., & Huber, P. E. (2011) · Neoplasia · doi:10.1593/neo.11258 · Cited by 94
Self-citationInhibiting TGF-β signaling in hepatocellular carcinoma
Giannelli, G., Mazzocca, A., Fransvea, E., Lahn, M., & Antonaci, S. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.11.004 · Cited by 90
Self-citationTGF-β inhibitors for the treatment of cancer
Lahn, M. M. F., Kloeker, S., & Berry, B. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.6.629 · Cited by 89
Self-citationAntibody Targeting of TGF-β in Cancer Patients
Lonning, S. M., Mannick, J. B., & McPherson, J. M. (2011) · Current Pharmaceutical Biotechnology · doi:10.2174/138920111798808392 · Cited by 89
Stevenson, J. P., Kindler, H. L., Papasavvas, E., Sun, J., Jacobs-Small, M., Hull, J., Schwed, D., Ranganathan, A., Newick, K., Heitjan, D. F., et al. (2013) · OncoImmunology · doi:10.4161/onci.26218 · Cited by 85
Vizán, P., Miller, D. S. J., Gori, I., Das, D., Schmierer, B., & Hill, C. S. (2013) · Science Signaling · doi:10.1126/scisignal.2004416 · Cited by 84
Feagins, L. A. (2010) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21281 · Cited by 83
Connolly, E. C., Saunier, E. F., Quigley, D., Luu, M. T., De Sapio, A., Hann, B., Yingling, J. M., & Akhurst, R. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2941 · Cited by 82
Hong, S., Lee, H.-J., Kim, S. J., & Hahm, K. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i17.2080 · Cited by 81
Gueorguieva, I., Cleverly, A., Stauber, A. J., Pillay, N. S., Rodon, J. A., Miles, C., Yingling, J. M., & Lahn, M. M. F. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12256 · Cited by 78
Self-citationThe Role of Shear-Induced Transforming Growth Factor-β Signaling in the Endothelium
Walshe, T. E., Paz, N. G. D., & D'Amore, P. A. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.302161 · Cited by 77
TGF-β signalling-related markers in cancer patients with bone metastasis
Baselga, J. M., Rothenberg, M. L., Tabernero, J. M., Seoane, J., Daly, T. M., Cleverly, A., Berry, B., Kloeker, S., RAY, C. A., Fill, J. A., et al. (2008) · Biomarkers · doi:10.1080/13547500701676019 · Cited by 76
Self-citationBiswas, S., Criswell, T. L., Wang, S. E., & Arteaga, C. L. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0952 · Cited by 69
Li, H., McMillen, W. T., Heap, C. R., McCann, D., Yan, L., Campbell, R. M., Mundla, S. R., King, C.-H. R., Dierks, E. A., Anderson, B. D., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701199p · Cited by 67
Self-citationWan, X., Li, Z.-G., Yingling, J. M., Yang, J., Starbuck, M. W., Ravoori, M. K., Kundra, V., Vazquez, E. S., & Navone, N. M. (2011) · Bone · doi:10.1016/j.bone.2011.11.022 · Cited by 66
Bharathy, S., Xie, W. Q., Yingling, J. M., & Reiß, M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5089 · Cited by 64
Kim, W. S., Park, C., Jung, Y. S., Kim, H. S., Han, J., Park, C. H., Kim, K., Kim, J., Shim, Y. M., & Park, K. (1999) · PubMed · Cited by 64
Bhattachar, S., Perkins, E. J., Tan, J. S., & Burns, L. J. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22669 · Cited by 62
Ostapoff, K. T., Cenik, B. K., Wang, M., Ye, R., Xu, X. N., Nugent, D. P., Hagopian, M. M., Topalovski, M., Rivera, L. B., Carroll, K. D., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1807 · Cited by 61
The TGFß pathway as a therapeutic target in cancer
Seoane, J. (2008) · Clinical & Translational Oncology · doi:10.1007/s12094-008-0148-2 · Cited by 59
BMP9 inhibits the proliferation and invasiveness of breast cancer cells MDA-MB-231
Wang, K., Feng, H., Ren, W., Sun, X., Luo, J., Tang, M., Zhou, L., Weng, Y., He, T., & Zhang, Y. (2011) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-011-1047-4 · Cited by 59
Flow-based pipeline for systematic modulation and analysis of 3D tumor microenvironments
Li, C. Y., Wood, D. K., Huang, J., & Bhatia, S. N. (2013) · Lab on a Chip · doi:10.1039/c3lc41300d · Cited by 52
Maier, A., Peille, A.-L., Vuaroqueaux, V., & Lahn, M. M. F. (2015) · Cellular Oncology · doi:10.1007/s13402-014-0210-8 · Cited by 51
Self-citationLi, Z., Chang, Z., Chiao, L. J., Kang, Y., Xia, Q., Zhu, C., Fleming, J. B., Evans, D. B., & Chiao, P. J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4002 · Cited by 51
Matsuzaki, K., Date, M., Furukawa, F., Tahashi, Y., Matsushita, M., Sugano, Y., Yamashiki, N., Nakagawa, T., Seki, T., Nishizawa, M., et al. (2000) · Hepatology · doi:10.1053/jhep.2000.9145 · Cited by 47
Wang, S. E., Yu, Y., Criswell, T. L., DeBusk, L. M., Lin, P., Zent, R., Johnson, D. H., Ren, X., & Arteaga, C. L. (2010) · Oncogene · doi:10.1038/onc.2010.112 · Cited by 47
Stauber, A. J. (2014) · Journal of Clinical Toxicology · doi:10.4172/2161-0495.196 · Cited by 46
Self-citationSerizawa, M., Takahashi, T., Yamamoto, N., & Koh, Y. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318279e942 · Cited by 45
Faivre, S. J., Santoro, A., Kelley, R. K., Merle, P., Gane, E. J., Douillard, J., Waldschmidt, D., Mulcahy, M. F., Costentin, C. E., Mínguez, B., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.3_suppl.lba173 · Cited by 45
Self-citationFransvea, E., Mazzocca, A., Santamato, A., Azzariti, A., Antonaci, S., & Giannelli, G. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1459-x · Cited by 44
COHN, A., LAHN, M. M., WILLIAMS, K. E., CLEVERLY, A. L., PITOU, C., KADAM, S. K., FARMEN, M. W., DESAIAH, D., RAJU, R., CONKLING, P., et al. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2679 · Cited by 43
Self-citationSingh, J., Ling, L., Js, S., Lee, W.-C., Zhang, F. P. Y., & Jm, Y. (2004) · PubMed · Cited by 40
Xu, Y., Tabe, Y., Jin, L., Watt, J. C., McQueen, T. J., Ohsaka, A., Andreeff, M., & Konopleva, M. Y. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07130.x · Cited by 39
Calvo, E., Baselga, J. M., Glatt, S., Cleverly, A., Lahn, M., Arteaga, C. L., Rothenberg, M. L., & Carducci, M. A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.14554 · Cited by 38
Self-citationLoeffler, M. W., Krüger, J. A., Niethammer, A. G., & Reisfeld, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci26532c1 · Cited by 38
Activin receptor-like kinase 1 as a target for anti-angiogenesis therapy
Hawinkels, L. J. A. C., de Vinuesa, A. G., & ten Dijke, P. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.837884 · Cited by 37
VEGFR2 Expression and TGF-β Signaling in Initial and Recurrent High-Grade Human Glioma
Kuczynski, E. A., Patten, S. G., & Coomber, B. L. (2011) · Oncology · doi:10.1159/000332849 · Cited by 36
Vázquez, P., Carlini, M. J., Daroqui, M. C., Colombo, L. L., Dalurzo, M. L., Smith, D. E., Grasselli, J., Pallotta, M. G., Ehrlich, M., Joffé, E. B. D. K., et al. (2013) · Clinical & Experimental Metastasis · doi:10.1007/s10585-013-9598-1 · Cited by 33
Hanks, B. A., Holtzhausen, A., Evans, K. S., Heid, M. E., & Blobe, G. C. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.3011 · Cited by 33
Wang, Q., Yu, T., Yuan, Y., Zhuang, H., Wang, Z., Liu, X.-S., & Feng, M. (2012) · Journal of Surgical Oncology · doi:10.1002/jso.23227 · Cited by 32
Rocchetti, M., Poggesi, I., Germani, M., Fiorentini, F., Pellizzoni, C., Zugnoni, P., Pesenti, E. A., Simeoni, M., & Nicolao, G. D. (2005) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2005.pto960325.x · Cited by 32
Rodon, J. A., Baselga, J. M., Calvo, E., Seoane, J., Braña, I., Sicart, E., Gueorguieva, I., Cleverly, A., Lahn, M., Pillay, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.3011 · Cited by 29
Self-citationLonardo, E., Hermann, P. C., Mueller, M.-T., Huber, S. M., Balic, A., Miranda‐Lorenzo, I., Zagorac, S., Alcalá, S., Rodríguez-Arabaolaza, I., Ramírez, J. C., et al. (2012) · Cell stem cell · doi:10.1016/j.stem.2011.12.001 · Cited by 29
Horie, M., Saito, A., Noguchi, S. F., Yamaguchi, Y., Ohshima, M., Morishita, Y., Suzuki, H. I., Kohyama, T., & Nagase, T. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-580 · Cited by 25
Development and validation of a phosphorylated SMADex vivostimulation assay
Farrington, D. L., Yingling, J. M., Fill, J. A., Yan, L., Qian, Y.-W., Shou, J., Wang, X., Ehsani, M. E., Cleverly, A., Daly, T. M., et al. (2007) · Biomarkers · doi:10.1080/13547500601162441 · Cited by 22
Self-citationLahn, M., Kunzmann, R., Köhler, G., Iklé, D. N., Hentrich, I., Jesuiter, H., Kulmburg, P., Veelken, H., Mackensen, A., Rosenthal, F. M., et al. (2009) · Oncology · doi:10.1159/000227730 · Cited by 14
Self-citationAnalysis and variability of TGFbeta measurements in cancer patients with skeletal metastases.
O'Brien, P. J., Ramanathan, R., Yingling, J. M., Baselga, J. M., Rothenberg, M. L., Carducci, M., Daly, T. M., Adcock, D. M., & Lahn, M. (2008) · PubMed Central · Cited by 13
Self-citationRodon, J. A., Carducci, M. A., Sepúlveda-Sánchez, J. M., Azaro, A., Calvo, E., Seoane, J., Braña, I., Sicart, E., Gueorguieva, I., Cleverly, A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.2016 · Cited by 13
Self-citationClaßen, S., Muth, C. A., Debey‐Pascher, S., Eggle, D., Beyer, M., Mallmann, M. R., Rudlowski, C., Zander, T., Pölcher, M., Kuhn, W. C., et al. (2010) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328335731c · Cited by 12
Self-citationAzaro, A., Baselga, J. M., Sepúlveda-Sánchez, J. M., Seoane, J., Rodon, J. A., Braña, I., Gueorguieva, I., Cleverly, A., Lahn, M. M. F., Pillay, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.2042 · Cited by 11
Self-citationLoh, J., Lieu, A., Su, Y., Cheng, C.-Y., Tsai, T., Lin, C., Lee, K., Hwang, S., Kwan, A., Wang, C., et al. (2012) · Cytokine · doi:10.1016/j.cyto.2012.11.011 · Cited by 9
Kozloff, M. F., García‐Carbonero, R., Nadal, T. S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.2563 · Cited by 9
Sepúlveda-Sánchez, J. M., Ramos, A., Hilario, A., de Velasco, G., Castellano, D., de la Torre, M. G., Rodon, J. A., & Lahn, M. (2015) · Oncology Letters · doi:10.3892/ol.2015.3106 · Cited by 7
Self-citationYingling, J. M. (2005) · Cancer Research · Cited by 7
Parsons, S. H., Sawyer, S., Yan, L., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-11-c201 · Cited by 5
Cleverly, S. K. A. L. (2013) · Journal of Molecular Biomarkers & Diagnosis · doi:10.4172/2155-9929.1000153 · Cited by 4
Azaro, A., Rodon, J. A., Carducci, M., Sepúlveda-Sánchez, J. M., Gueorguieva, I., Cleverly, A., Desaiah, D., Namaseevayam, S. P., Holdhoff, M., & Lahn, M. M. F. (2014) · Journal of Medical Cases · doi:10.14740/jmc1966w · Cited by 2
Self-citation
Cited by
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Targeting TGF-β signal transduction for fibrosis and cancer therapy
Peng, D., Fu, M., Wang, M., Wei, Y., & Wei, X. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01569-x · Cited by 1,065
Targeting TGF-β Signaling in Cancer
Colak, S., & ten Dijke, P. (2017) · Trends in cancer · doi:10.1016/j.trecan.2016.11.008 · Cited by 1,003
TGFβ biology in cancer progression and immunotherapy
Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944
Targeting Epithelial–Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer
Du, B., & Shim, J. (2016) · Molecules · doi:10.3390/molecules21070965 · Cited by 807
Metadata
- Authors
- Lahn, M., Herbertz, S., Sawyer, J. S., Stauber, A. J., Gueorguieva, I., Driscoll, K. E., Estrem, S. T., Cleverly, A. L., Desaiah, D., Guba, S. C., Benhadji, K. A., & Slapak, C. A.
- Venue
- Drug Design, Development and Therapy
- Publisher
- Informa UK Limited
- Published
- 2015-08
- Volume
- 9
- Pages
- 4479
- ISSN
- 1177-8881 (ISSN-L)
- OpenAlex
- W1700691315
- Cited by
- 554
- References
- 154
- FWCI
- 18.65
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.